Artwork

Content provided by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

56:55
 
Share
 

Manage episode 424795589 series 2738732
Content provided by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

In this episode, we discuss:

  • The FDA advisory committee process and its implications for drug approvals
  • Functional unblinding and expectancy effects in psychedelic clinical trials
  • Potential impacts on the broader psychedelic medicine industry
  • The future of psychedelic-assisted psychotherapy protocols
  • Neuroplastogen development and non-hallucinogenic approaches
  • Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

  continue reading

51 episodes

Artwork
iconShare
 
Manage episode 424795589 series 2738732
Content provided by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

In this episode, we discuss:

  • The FDA advisory committee process and its implications for drug approvals
  • Functional unblinding and expectancy effects in psychedelic clinical trials
  • Potential impacts on the broader psychedelic medicine industry
  • The future of psychedelic-assisted psychotherapy protocols
  • Neuroplastogen development and non-hallucinogenic approaches
  • Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

  continue reading

51 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide